In conclusion, MC receptors represent novel targets for the development of innovative therapies for RA and other inflammatory diseases: targeting MC3 using PAMs constitutes a viable and biologically effective means to reduce synovial inflammation. This evidence concerns the gene MC3R and rheumatoid arthritis.